Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)
Open Access
- 18 August 2023
- journal article
- research article
- Published by Elsevier in eClinicalMedicine
- Vol. 63, 102160
Abstract
No abstract availableKeywords
Funding Information
- National Center for Genetic Engineering and Biotechnology
This publication has 21 references indexed in Scilit:
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trialThe Lancet Infectious Diseases, 2021
- COVID‐19 vaccines are effective in people with obesity: A position statement from The Obesity SocietyObesity, 2021
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trialThe Lancet Infectious Diseases, 2021
- Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2Nature, 2021
- Considering Mandatory Vaccination of Children for COVID-19Pediatrics, 2021
- Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?Clinical Infectious Diseases, 2020
- Evaluation of SARS‐CoV‐2 neutralizing antibodies using a CPE‐based colorimetric live virus micro‐neutralization assay in human serum samplesJournal of Medical Virology, 2020
- Influence of immune aging on vaccine responsesJournal of Allergy and Clinical Immunology, 2020
- Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adultsHuman Vaccines, 2011
- Large-scale production of recombinant hepatitis B surface antigen from Pichia pastorisJournal of Biotechnology, 2000